During the past decade, Swedish Neuroscience Institute conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 14 clinical trials were completed, i.e. on average, 56% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 10 clinical trials were completed. i.e. 111.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Swedish Neuroscience Institute" #1 sponsor was "Boston Scientific Corporation" with 4 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Novartis Pharmaceuticals" with 3 trials sponsored, "Alexion" with 2 trials sponsored and "Amylyx Pharmaceuticals Inc." with 2 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Swedish Neuroscience Institute" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "NeuroNEXT Network" with 2 trials as a collaborator, "Autoimmunity Centers of Excellence" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Biogen" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Swedish Neuroscience Institute" are "Amyotrophic Lateral Sclerosis" (6 trials), "Glioblastoma Multiforme" (6 trials), "Multiple Sclerosis" (6 trials), "Multiple Sclerosis, Relapsing-Remitting" (3 trials) and "Acromegaly" (2 trials). Many other conditions were trialed in "Swedish Neuroscience Institute" in a lesser frequency.

Most popular intervention types in "Swedish Neuroscience Institute" are "Drug" (32 trials), "Biological" (8 trials), "Device" (8 trials), "Other" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Ocrelizumab" (4 trials), "Bevacizumab" (3 trials), "Temozolomide" (3 trials) and "AMX0035" (2 trials). Other intervention names were less common.

The vast majority of trials in "Swedish Neuroscience Institute" are 46 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Swedish Neuroscience Institute". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Swedish Neuroscience Institute, 1 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Swedish Neuroscience Institute, 3 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 4 trials that are defined as “Not Applicable".